DJIA 18,034.93 208.63 1.17%
NASDAQ 4,994.60 62.79 1.27%
S&P 500 2,100.40 19.22 0.92%
market minute promo

Gilead Sciences (NASDAQ: GILD)

100.66 -0.73 (-0.72%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $100.66 -0.72%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $102.28
Previous Close $101.38
Daily Range $100.41 - $102.28
52-Week Range $69.40 - $116.83
Market Cap $149.9B
P/E Ratio 13.79
Dividend (Yield) $0.00 (0.0%)
Volume 8,747,471
Average Daily Volume 10,831,627
Current FY EPS $10.18

Sector

Healthcare

Industry

Drug Makers

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary

Double-Digit Spike in Drug Costs Prescribes Profits for PBMs

A new report by employee benefit consultancy Aon Hewitt forecasts a 10% increase in employer drug costs through 2017, which puts a spotlight on pharmacy benefit management companies to assist employers, health plans, and government insurers such as Medicare and Medicaid to control prescription spending.

Weekly CFO Sells Highlight: Gilead Sciences Inc, CarMax Inc, Anthem Inc.

Gilead Sciences: Serious Cash Means An Acquisition Could Be Coming Soon

Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals

Core Healthcare Companies In My Income And Growth Portfolio

Why This Trader Likes Gilead Better Than Biogen

How to Invest Money in Biotech

If you want to invest money in biotech, you first need to understand what catalysts tend to determine biotech stock valuations, and what your three best pathways are to becoming a successful biotech investor.

3 Biotech Stocks That Could Be Developing Billion Dollar Drugs

These three clinical stage biotech companies are working on therapies addressing billion dollar indications.

3 Drug Stocks Leading the Charge Against Infectious Diseases

Our experts weigh in.

Morningstar: Gilead Sciences To Grow Its Hepatitis C Market

See More GILD News...

GILD's Top Competitors

GILD $100.66 (-0.72%)
Current stock: GILD
CELG $114.75 (1.13%)
Current stock: CELG
$0.00 (0.00%)
Current stock:
BIIB $422.92 (0.83%)
Current stock: BIIB